TNXP (Tonix Pharmaceuticals Holding) Return on Sales by Gross Profit

TNXP (Tonix Pharma) - company brandmark

Tonix Pharmaceuticals focuses on fibromyalgia and CNS therapies while awaiting FDA approval for Tonmya. The massive potential of the chronic pain market paves the way for expanding the customer base. The operating gross margin demonstrates real profitability, where 84.00 determines the current value of the metric. The drug development process is accelerating through AI-driven molecular screening and automated tablet synthesis.

TNXP - tonixpharma.com Return on Gross Profit over the range 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Tonix Pharmaceuticals (TNXP)

Fundamental valuation:Tonix Pharmaceuticals
Product sample of Tonix Pharmaceuticals Holding

Gross margin measures the portion of revenue remaining after covering direct production costs, allowing for an assessment of the core efficiency of profit generation. The current value of 84.00 and the gross margin profitability trend reflect the impact of Tonix Pharmaceuticals proprietary molecules, where a closed portfolio of CNS drugs reduces competition and stabilizes the realization value relative to development costs.

Main competitors

Gross Profit Margin Haleon PLC (HLN)|Return on Gross Profit KVUE|Gross Profit Margin Verona Pharma Inc. VRNA|Gross Margin MENS|Ligand Pharmaceuticals - Gross Return on Sales|Gross Profitability Amneal AMRX|Gross Sales Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Gross Margin|Return on Sales by Gross Profit Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Gross Profitability|anipharmaceuticals.com - Gross Profit Rate|Return on Gross Profit MNKD|AMPH: Gross Profit Rate|Gross Profitability pacira.com (PCRX)|Gross Margin ARS Pharma (SPRY)|Theravance Biopharma - Return on Gross Profit|Gross Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Return on Gross Profit|Gross Profit Margin Tectonic Therapeutic|SXTC: Gross Margin|Eupraxia Pharma - Gross Profit Rate|BHST (bioharvest.com) - Gross Margin|Gross Return on Sales EXOZ (invizyne.com)|Gross Margin ORMP|Return on Sales by Gross Profit Entera Bio|Gross Margin HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Gross Profitability|Cumberland Corp - Gross Margin|QNTM - Gross Margin|FibroGen, Inc. (FGEN) - Gross Profitability|TELO: Gross Profit Ratio|RANI (Rani Therapeutics Inc) - Gross Margin|Gross Profit Margin synergychc.com SNYR|Gross Profitability Rallybio Corp. (RLYB)|LEXX - Gross Profit Margin|Gross Margin PULM (pulmatrix.com)|Gross Profit Ratio PTHL (Pheton)|APM - Gross Profitability|Return on Sales by Gross Profit Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Gross Profitability|TNF Pharma (TNFA) - Gross Margin|YCBD (cbdmd.com) - Gross Margin|Return on Gross Profit PainReform (PRFX)|Gross Profitability Altamira Therapeutics (CYTO)|Return on Sales by Gross Profit Lipella Pharma|Optinose - Return on Gross Profit|Return on Sales by Gross Profit pieris.com (PIRS)|PROC - Gross Profitability|Gross Profitability Margin PTPI|QLI: Gross Margin|Gross Profit Margin ACELYRIN Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Gross Margin